tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

OCUP Stock Latest News

Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options
Company AnnouncementsOcuphire Pharma Incentivizes Director Pepose with Stocks and Options
8d ago
8K
OCUP
Ocuphire Pharma announces enrollment of first patient in LYNX-2 Phase 3 study
PremiumThe Fly
Ocuphire Pharma announces enrollment of first patient in LYNX-2 Phase 3 study
14d ago
OCUP
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
PremiumPress Releases
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
14d ago
OCUP
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
PremiumPress Releases
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
24d ago
OCUP
Ocuphire Pharma announces U.S. commercial launch of RYZUMVI
PremiumThe Fly
Ocuphire Pharma announces U.S. commercial launch of RYZUMVI
24d ago
OCUP
VTRS
Ocuphire Pharma Engages Investors with Presentation Update
PremiumCompany AnnouncementsOcuphire Pharma Engages Investors with Presentation Update
29d ago
8K
OCUP
Ocuphire Pharma price target lowered to $20 from $24 at Alliance Global
PremiumThe Fly
Ocuphire Pharma price target lowered to $20 from $24 at Alliance Global
1M ago
OCUP
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
PremiumPress Releases
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
2M ago
OCUP
Ocuphire Pharma expects cash to fund operations into mid-2025
PremiumThe Fly
Ocuphire Pharma expects cash to fund operations into mid-2025
2M ago
OCUP
Ocuphire Pharma reports Q4 EPS (21c), consensus (5c)
PremiumThe Fly
Ocuphire Pharma reports Q4 EPS (21c), consensus (5c)
2M ago
OCUP
OCUP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
OCUP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
OCUP
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
PremiumPress Releases
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
2M ago
OCUP
Ocuphire Pharma Welcomes Nirav Jhaveri as New CFO
PremiumCompany AnnouncementsOcuphire Pharma Welcomes Nirav Jhaveri as New CFO
2M ago
8K
OCUP
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2M ago
OCUP
Ocuphire Pharma appoints Jayagopal as CSDO, Jhaveri as CFO
PremiumThe Fly
Ocuphire Pharma appoints Jayagopal as CSDO, Jhaveri as CFO
2M ago
OCUP
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
PremiumPress Releases
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
2M ago
OCUP
Ocuphire Pharma announces presentation on APX3330
PremiumThe Fly
Ocuphire Pharma announces presentation on APX3330
3M ago
OCUP
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
PremiumPress Releases
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
3M ago
OCUP
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3M ago
OCUP
Ocuphire Pharma files $175M mixed securities shelf
PremiumThe FlyOcuphire Pharma files $175M mixed securities shelf
4M ago
OCUP
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
PremiumPress Releases
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
4M ago
OCUP
Ocuphire Pharma receives FDA agreement under SPA for LYNX-2 Phase 3 trial
PremiumThe Fly
Ocuphire Pharma receives FDA agreement under SPA for LYNX-2 Phase 3 trial
4M ago
OCUP

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >